NUVALENT INC
NASDAQ: NUVL (Nuvalent, Inc.)
Last update: yesterday, 3:50PM80.30
-1.76 (-2.14%)
| Previous Close | 82.06 |
| Open | 81.25 |
| Volume | 396,998 |
| Avg. Volume (3M) | 428,408 |
| Market Cap | 5,705,524,224 |
| Price / Book | 5.24 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.49 |
| Current Ratio (MRQ) | 23.07 |
| Operating Cash Flow (TTM) | -153.27 M |
| Levered Free Cash Flow (TTM) | -81.21 M |
| Return on Assets (TTM) | -18.63% |
| Return on Equity (TTM) | -29.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nuvalent, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.83% |
| % Held by Institutions | 108.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 30 Sep 2024 | 1,687,064 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 134.00 (BMO Capital, 66.87%) | Buy |
| Median | 125.00 (55.67%) | |
| Low | 100.00 (UBS, 24.53%) | Hold |
| Average | 119.67 (49.03%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 96.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 13 Nov 2024 | 134.00 (66.87%) | Buy | 90.34 |
| UBS | 24 Oct 2024 | 100.00 (24.53%) | Hold | 93.63 |
| JP Morgan | 04 Oct 2024 | 125.00 (55.67%) | Buy | 104.93 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BALCOM ALEXANDRA | - | - | 0 | 0 |
| PELISH HENRY E. | - | - | 0 | 0 |
| PORTER JAMES RICHARD | - | 87.42 | -27,000 | -2,360,340 |
| Aggregate Net Quantity | -27,000 | |||
| Aggregate Net Value ($) | -2,360,340 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 87.42 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PORTER JAMES RICHARD | Officer | 19 Dec 2024 | Option execute | 22,000 | - | - |
| BALCOM ALEXANDRA | Officer | 17 Dec 2024 | Option execute | 13,700 | - | - |
| PORTER JAMES RICHARD | Officer | 16 Dec 2024 | Automatic sell (-) | 27,000 | 87.42 | 2,360,340 |
| PORTER JAMES RICHARD | Officer | 16 Dec 2024 | Option execute | 27,000 | - | - |
| PELISH HENRY E. | Officer | 16 Dec 2024 | Option execute | 10,414 | - | - |
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 09 Dec 2024 | Announcement | Nuvalent Appoints Grant Bogle to Board of Directors |
| 26 Nov 2024 | Announcement | Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| 12 Nov 2024 | Announcement | Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results |
| 28 Oct 2024 | Announcement | From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |